prikaz prve stranice dokumenta Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients
  Download
PDF 338.86 KB
Scientific paper - Original scientific paper
Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients
Acta clinica Croatica, 58 (2019), 3; 455-462. https://doi.org/10.20471/acc.2019.58.03.08
Mihić, Josip; Rotim, Krešimir; Vučić, Majda; Hude Dragičević, Ida; Borić, Marta; Lugović-Mihić, Liborija

Cite this document

Mihić, J., Rotim, K., Vučić, M., Hude Dragičević, I., Borić, M. & Lugović Mihić, L. (2019). Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients. Acta clinica Croatica, 58. (3), 455-462. doi: 10.20471/acc.2019.58.03.08

Mihić, Josip, et al. "Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients." Acta clinica Croatica, vol. 58, no. 3, 2019, pp. 455-462. https://doi.org/10.20471/acc.2019.58.03.08

Mihić, Josip, Krešimir Rotim, Majda Vučić, Ida Hude Dragičević, Marta Borić and Liborija Lugović Mihić. "Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients." Acta clinica Croatica 58, no. 3 (2019): 455-462. https://doi.org/10.20471/acc.2019.58.03.08

Mihić, J., et al. (2019) 'Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients', Acta clinica Croatica, 58(3), pp. 455-462. doi: 10.20471/acc.2019.58.03.08

Mihić J, Rotim K, Vučić M, Hude Dragičević I, Borić M, Lugović Mihić L. Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients. Acta clinica Croatica [Internet]. 2019 [cited 2024 October 05];58(3):455-462. doi: 10.20471/acc.2019.58.03.08

J. Mihić, K. Rotim, M. Vučić, I. Hude Dragičević, M. Borić and L. Lugović Mihić, "Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients", Acta clinica Croatica, vol. 58, no. 3, pp. 455-462, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:078248. [Accessed: 05 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients
Title (croatian)Prognostička vrijednost ekspresije CD44 i neovaskularizacije određene endoglinom (CD05) u bolesnika s glioblastomom
AuthorJosip Mihić
AuthorKrešimir Rotim
AuthorMajda Vučić
AuthorIda Hude Dragičević
AuthorMarta Borić
AuthorLiborija Lugović-Mihić
MBZ: 215056
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Clinically useful molecular markers that help predict response to therapy and prognosis are still rare. The research was conducted in 55 patients with GBM, 26 (47.3%) women and 29 (52.7%) men, mean age 62.58 years. On immunohistochemical analysis, primary antibody to CD44 (dilution 1:50) and primary antibody to endoglin (CD105) (dilution 1:250) were used to evaluate neovascularization. Statistical analysis showed negative correlation between CD44 and survival (p=0.023) (higher expression of CD44 was correlated with shorter survival), but there was no correlation between neovascularization determined by CD105 in GBM and patient survival. Thus, significant individual predictors of longer survival were lower expression of CD44 (p=0.004), higher Karnofsky score (p=0.045), and female gender (p=0.017). The results obtained suggested the possible role of CD44 in the progression and tumor neovascularization of GBM.
Abstract (croatian)
Glioblastom multiforme (GBM) je najčešći i najagresivniji maligni primarni tumor mozga u ljudi. Postoje tek rijetki molekularni biljezi koji su klinički korisni te pomažu u predviđanju odgovora na terapiju i u prognozi bolesti. Istraživanje je provedeno kod 55 bolesnika s GBM, 26 (47,3%) žena i 29 (52,7%) muškaraca, prosječne dobi od 62,58 godina. U imunohistokemijskoj analizi je za procjenu neovaskularizacije korišteno primarno antitijelo prema CD44 (razrjeđenje 1:50) i primarno antitijelo prema endoglinu (CD105) (razrjeđenje 1:250). Statistička analiza je pokazala negativnu korelaciju između CD44 i preživljenja (p=0,023) (veća ekspresija CD44 je korelirala s kraćim preživlje-njem), ali nije bilo korelacije između neovaskularizacije (određene putem CD105) kod GBM i preživljenja ovih bolesnika. Tako su značajni pojedinačni prediktori dužeg preživljenja bili niža ekspresija CD44 (p=0,004), veći Karnofskyjev zbir (p=0,045) i ženski spol (p=0,017). Dobiveni rezultati ukazuju na moguću ulogu CD44 u progresiji i tumorskoj neovaskularizaciji kod GBM.
Keywords (english)
Keywords (croatian)
Languageenglish
Languagecroatian
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleActa clinica Croatica
Numberingvol. 58, no. 3, pp. 455-462
p-ISSN0353-9466
e-ISSN1333-9451
DOIhttps://doi.org/10.20471/acc.2019.58.03.08
URN:NBNurn:nbn:hr:220:078248
Publication2019
Document URLhttps://hrcak.srce.hr/230177
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2024-06-24 08:16:26